- Home
- TCRX vs PROK Comparison
TCRX vs PROK Comparison
Compare TCRX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- PROK
- Stock Information
- Founded
- TCRX 2018
- PROK 2015
- Country
- TCRX United States
- PROK United States
- Employees
- TCRX N/A
- PROK N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCRX Health Care
- PROK Health Care
- Exchange
- TCRX Nasdaq
- PROK Nasdaq
- Market Cap
- TCRX 82.1M
- PROK 85.5M
- IPO Year
- TCRX 2021
- PROK N/A
- Fundamental
- Price
- TCRX $1.93
- PROK $3.29
- Analyst Decision
- TCRX Strong Buy
- PROK Buy
- Analyst Count
- TCRX 6
- PROK 5
- Target Price
- TCRX $9.50
- PROK $6.25
- AVG Volume (30 Days)
- TCRX 572.1K
- PROK 37.7M
- Earning Date
- TCRX 08-11-2025
- PROK 08-08-2025
- Dividend Yield
- TCRX N/A
- PROK N/A
- EPS Growth
- TCRX N/A
- PROK N/A
- EPS
- TCRX N/A
- PROK N/A
- Revenue
- TCRX $4,421,000.00
- PROK $306,000.00
- Revenue This Year
- TCRX $159.20
- PROK $85.21
- Revenue Next Year
- TCRX N/A
- PROK N/A
- P/E Ratio
- TCRX N/A
- PROK N/A
- Revenue Growth
- TCRX N/A
- PROK N/A
- 52 Week Low
- TCRX $1.02
- PROK $0.46
- 52 Week High
- TCRX $7.44
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- TCRX 63.03
- PROK 60.03
- Support Level
- TCRX $1.75
- PROK $2.80
- Resistance Level
- TCRX $1.96
- PROK $4.05
- Average True Range (ATR)
- TCRX 0.14
- PROK 1.11
- MACD
- TCRX 0.01
- PROK -0.07
- Stochastic Oscillator
- TCRX 94.00
- PROK 37.15
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.